Literature DB >> 8221662

The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

S M Freeman1, C N Abboud, K A Whartenby, C H Packman, D S Koeplin, F L Moolten, G N Abraham.   

Abstract

Tumor cells expressing the herpes simplex virus thymidine kinase (HSV-TK) gene are sensitive to the drug ganciclovir (GCV). We demonstrate here that HSV-TK-positive cells exposed to GCV were lethal to HSV-TK-negative cells as a result of a "bystander effect." HSV-TK-negative cells were killed in vitro when the population of cultured cells contained only 10% HSV-TK-positive cells. The mechanism of this "bystander effect" on HSV-TK-negative cells appeared to be related to the process of apoptotic cell death when HSV-TK-positive cells were exposed to GCV. Flow cytometric and electron microscopic analyses suggested that apoptotic vesicles generated from the dying gene-modified cells were phagocytized by nearby, unmodified tumor cells. Prevention of apoptotic vesicle transfer prevented the bystander effect. The toxic effect of HSV-TK-positive cells on HSV-TK-negative cells was reproduced in an in vivo model. A mixed population of tumor cells consisting of HSV-TK-positive and HSV-TK-negative cells was inoculated s.c. into mice. Regression of the tumor mass occurred when the inoculum consisted of as few as 10% HSV-TK-expressing tumor cells. The bystander effect was also demonstrated in i.p. tumor studies. Initial experiments demonstrated that prolonged survival (> 70 days) occurred when a mixture containing 50% HSV-TK-positive and 50% HSV-TK-negative cells was injected i.p. followed by GCV treatment. Further, survival was prolonged for mice with a preexisting HSV-TK-negative i.p. tumor burden by injecting HSV-TK-positive cells and GCV. These results suggest that genetic modification of tumor cells may be useful for developing cancer therapies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221662

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  178 in total

Review 1.  Therapeutic genes for cancer gene therapy.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1999-11       Impact factor: 2.695

2.  Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries.

Authors:  R D Simari; H San; M Rekhter; T Ohno; D Gordon; G J Nabel; E G Nabel
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 3.  Clinical trials with retrovirus mediated gene therapy--what have we learned?

Authors:  Nikolai G Rainov; Huan Ren
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

4.  The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro.

Authors:  J Fick; F G Barker; P Dazin; E M Westphale; E C Beyer; M A Israel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

5.  Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.

Authors:  Katharine M Hardy; Luigi Strizzi; Naira V Margaryan; Kanika Gupta; George F Murphy; Richard A Scolyer; Mary J C Hendrix
Journal:  Mol Cancer Res       Date:  2015-03-12       Impact factor: 5.852

6.  Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

Authors:  Cun-Zhi Lin; Gui-Ling Xiang; Xin-Hong Zhu; Lu-Lu Xiu; Jia-Xing Sun; Xiao-Yuan Zhang
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

7.  Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors.

Authors:  D Barba; J Hardin; M Sadelain; F H Gage
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

8.  TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer.

Authors:  Shan-Yu Guo; Qin-Long Gu; Zheng-Gang Zhu; He-Qun Hong; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

9.  Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.

Authors:  W R Smythe; H C Hwang; A A Elshami; K M Amin; S L Eck; B L Davidson; J M Wilson; L R Kaiser; S M Albelda
Journal:  Ann Surg       Date:  1995-07       Impact factor: 12.969

10.  Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir.

Authors:  L Yang; R Hwang; L Pandit; E M Gordon; W F Anderson; D Parekh
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.